Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free DXCM Stock Alerts $134.88 -2.99 (-2.17%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$134.71▼$139.2450-Day Range$114.22▼$140.4552-Week Range$74.75▼$142.00Volume131,265 shsAverage Volume2.93 million shsMarket Capitalization$53.42 billionP/E Ratio102.96Dividend YieldN/APrice Target$141.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get DexCom alerts: Email Address DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside2.6% Upside$141.40 Price TargetShort InterestHealthy3.68% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.76Based on 13 Articles This WeekInsider TradingSelling Shares$25.53 M Sold Last QuarterProj. Earnings Growth26.70%From $1.76 to $2.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.40 out of 5 starsMedical Sector107th out of 907 stocksSurgical & Medical Instruments Industry17th out of 96 stocks 1.5 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.68% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in DexCom has recently decreased by 8.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 3.2 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for DexCom this week, compared to 12 articles on an average week.Search InterestOnly 18 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows28 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 12% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,530,859.00 in company stock.Percentage Held by InsidersOnly 0.41% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 26.70% in the coming year, from $1.76 to $2.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 105.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.29.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 105.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 191.01.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 25.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesApril 18, 2024 | insidertrades.comDexCom, Inc. (NASDAQ:DXCM) EVP Sells $274,241.90 in StockApril 11, 2024 | insidertrades.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) CEO Sells 49,633 Shares of StockApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 2, 2024 | marketbeat.comDexCom Stock Gains from GLP-1 Diabetic UsersDexCom Inc. NASDAQ: DXCM is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to monitor their blood glucose levels.April 2, 2024 | marketbeat.comDexCom Stock Gains from GLP-1 Diabetic UsersDexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. PeopleMarch 31, 2024 | insidertrades.comMichael Jon Brown Sells 2,624 Shares of DexCom, Inc. (NASDAQ:DXCM) StockMarch 27, 2024 | insidertrades.comDexCom, Inc. (NASDAQ:DXCM) EVP Sells $579,180.00 in StockApril 25, 2024 | investorplace.comMedtech Marvels: 3 Groundbreaking Medical Device Stocks to Watch in 2024April 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 24, 2024 | americanbankingnews.comDexCom (NASDAQ:DXCM) Downgraded to Hold at StockNews.comApril 20, 2024 | nasdaq.comFirst Week of December 20th Options Trading For DexCom (DXCM)April 19, 2024 | finance.yahoo.comEven IBD 50 Medical Products Stocks Don't All Look Healthy In This Sick MarketApril 19, 2024 | finance.yahoo.comDexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next WeekApril 19, 2024 | americanbankingnews.comMatthew Vincent Dolan Sells 1,990 Shares of DexCom, Inc. (NASDAQ:DXCM) StockApril 18, 2024 | finance.yahoo.comDexCom, Inc. (DXCM)April 18, 2024 | americanbankingnews.comDexCom (DXCM) Set to Announce Earnings on ThursdayApril 17, 2024 | benzinga.com$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much TodayApril 17, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Dexcom (DXCM)April 16, 2024 | finance.yahoo.comEVP Strategy and Corporate Dev Matthew Dolan Sells Shares of DexCom Inc (DXCM)April 15, 2024 | finance.yahoo.comDexCom (DXCM) Stock Moves -1.16%: What You Should KnowApril 12, 2024 | investors.comWhy Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To BenefitApril 11, 2024 | reuters.comColumn: 9th Circuit punts on viability of ‘snap’ removals but bars ‘super snaps’April 11, 2024 | seekingalpha.comDexCom Is Pricey For A Reason - Its Growth Story Reflects ThatApril 10, 2024 | finance.yahoo.comInsider Sell: DexCom Inc (DXCM) President, CEO and Chairman Kevin Sayer Sells 49,633 SharesApril 10, 2024 | markets.businessinsider.comThe Analyst Verdict: DexCom In The Eyes Of 4 ExpertsApril 10, 2024 | investorplace.comNasdaq Nightmares: 3 Stocks to Sell Before Reality Sets InApril 10, 2024 | investorplace.com3 Obesity Drug Stocks Set to Skyrocket as Demand Goes WildSee More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/25/2024Next Earnings (Confirmed)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$141.40 High Stock Price Target$165.00 Low Stock Price Target$100.00 Potential Upside/Downside+2.6%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$1.31 Trailing P/E Ratio105.25 Forward P/E Ratio78.34 P/E Growth2.26Net Income$541.50 million Net Margins14.95% Pretax Margin19.61% Return on Equity28.31% Return on Assets9.74% Debt Debt-to-Equity Ratio1.18 Current Ratio2.84 Quick Ratio2.48 Sales & Book Value Annual Sales$3.62 billion Price / Sales14.67 Cash Flow$2.17 per share Price / Cash Flow63.56 Book Value$5.35 per share Price / Book25.77Miscellaneous Outstanding Shares385,520,000Free Float383,934,000Market Cap$53.15 billion OptionableOptionable Beta1.20 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 66)Executive Chairman, CEO & President Comp: $2.22MMr. Jereme M. Sylvain (Age 44)Executive VP, CFO & Chief Accounting Officer Comp: $841.14kMr. Jacob Steven Leach (Age 46)Executive VP & COO Comp: $994.13kMr. Girish Naganathan (Age 47)Executive VP & CTO Comp: $423.92kMr. Michael Jon Brown (Age 54)Executive VP & Chief Legal Officer Comp: $954.46kMr. Shelly Ramasamy Selvaraj (Age 65)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 43)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne MarshExecutive Vice President of MarketingMs. Sadie M. Stern (Age 49)Executive VP & Chief Human Resources Officer More ExecutivesKey Competitors3MNYSE:MMMResMedNYSE:RMDBaxter InternationalNYSE:BAXAbiomedNASDAQ:ABMDInsuletNASDAQ:PODDView All CompetitorsInsiders & InstitutionsCambridge Investment Research Advisors Inc.Sold 16,667 shares on 4/25/2024Ownership: 0.013%CENTRAL TRUST CoSold 155 shares on 4/24/2024Ownership: 0.001%Premier Path Wealth Partners LLCSold 151 shares on 4/24/2024Ownership: 0.001%Newbridge Financial Services Group Inc.Sold 1,134 shares on 4/24/2024Ownership: 0.001%Spire Wealth ManagementBought 320 shares on 4/24/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions DXCM Stock Analysis - Frequently Asked Questions Should I buy or sell DexCom stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price target for 2024? 14 equities research analysts have issued 12-month price targets for DexCom's stock. Their DXCM share price targets range from $100.00 to $165.00. On average, they expect the company's stock price to reach $141.40 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2024? DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM shares have increased by 11.1% and is now trading at $137.87. View the best growth stocks for 2024 here. Are investors shorting DexCom? DexCom saw a drop in short interest in March. As of March 31st, there was short interest totaling 14,570,000 shares, a drop of 8.2% from the March 15th total of 15,870,000 shares. Based on an average trading volume of 3,090,000 shares, the short-interest ratio is presently 4.7 days. View DexCom's Short Interest. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our DXCM earnings forecast. How can I listen to DexCom's earnings call? DexCom will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) released its earnings results on Thursday, February, 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. The medical device company earned $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a trailing twelve-month return on equity of 28.31% and a net margin of 14.95%. The company's quarterly revenue was up 26.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.34 earnings per share. Read the conference call transcript. What ETFs hold DexCom's stock? ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Internet of Things Thematic ETF (SNSR), Global X Telemedicine & Digital Health ETF (EDOC), Subversive Mental Health ETF (SANE), Fidelity Digital Health ETF (FDHT), American Century Mid Cap Growth Impact ETF (MID), iShares U.S. Medical Devices ETF (IHI) and Tema Cardiovascular and Metabolics ETF (HRTS). When did DexCom's stock split? DexCom shares split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). Who are DexCom's major shareholders? DexCom's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.37%), Allspring Global Investments Holdings LLC (0.33%), Congress Asset Management Co. MA (0.29%), Raymond James & Associates (0.27%), Sumitomo Mitsui Trust Holdings Inc. (0.26%) and Raymond James Financial Services Advisors Inc. (0.15%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More This page (NASDAQ:DXCM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceNew Trump BombshellThe Freeport SocietyGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
